<?xml version="1.0" encoding="UTF-8"?>
<ref id="R31">
 <label>31</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Shah</surname>
    <given-names>NJ</given-names>
   </name>, 
   <name name-style="western">
    <surname>Al-Shbool</surname>
    <given-names>G</given-names>
   </name>, 
   <name name-style="western">
    <surname>Blackburn</surname>
    <given-names>M</given-names>
   </name>, 
   <etal>et al</etal>
  </person-group>
  <article-title>Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection</article-title>. 
  <source>J Immunother Cancer</source>
  <year>2019</year>;
  <volume>7</volume>:
  <fpage>353</fpage>. 
  <pub-id pub-id-type="doi">10.1186/s40425-019-0771-1</pub-id>
  <?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/31847881?>
  <pub-id pub-id-type="pmid">31847881</pub-id>
 </mixed-citation>
</ref>
